Abstract

Autoimmune polyglandular syndromes (APS) are a diverse group of clinical conditions characterized by loss of immune tolerance in various tissues. This condition can be diagnosed in childhood or adulthood, with changes in the components of the disease throughout life. Here, an unusual case of association between immune-mediated diseases will be addressed: Myasthenia Gravis, Systemic Lupus Erythematosus, and Celiac Disease. In this patient, each disease was expressed over time. Finally, we assume that this is a clinical form of APS type IV, due to the lack of thyroid involvement to date.

Highlights

  • Autoimmune polyglandular syndromes (APS) are a diverse group of clinical conditions characterized by loss of immune tolerance in various tissues

  • Due to the clinical presentation of the patient with 3 organ-specific autoimmune diseases, which does not fit the criteria for polyglandular syndrome type I, II, or III, we believe it is a clinical form of Autoimmune Polyglandular Syndrome type IV

  • APS type 4 is represented by the association between other endocrine disorders or autoimmune diseases [6], as was the case of the patient previously reported in this article, who presented myasthenia gravis, systemic lupus erythematosus, and celiac disease

Read more

Summary

Introduction

Signs and symptoms include alopecia, vitiligo, celiac disease, myasthenia gravis, autoimmune gastritis with vitamin B12 deficiency. This condition can be diagnosed in childhood or adulthood, with changes in the components of the disease throughout life [1]. An unusual case of association between immune-mediated diseases will be addressed: Myasthenia Gravis, Systemic Lupus Erythematosus, and Celiac Disease. In this patient, each disease was expressed over time. The patient gave birth to her second child During pregnancy, she used Hydroxychloroquine Sulfate (3mg/kg/day) to prevent the increased activity or cause worsening of Lupus disease. Due to the clinical presentation of the patient with 3 organ-specific autoimmune diseases, which does not fit the criteria for polyglandular syndrome type I, II, or III, we believe it is a clinical form of Autoimmune Polyglandular Syndrome type IV

Discussion
Findings
Conclusion
Ethical Compliance Statement
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.